53P - Assessment of cancer testis antigen 45 for diagnostic and prognostic applications in ovarian cancer

Background

High-grade serous carcinoma (HGSC) is recognized as the most aggressive form of ovarian cancer (OC), with frequent recurrence despite treatment. Recently, the CT45 gene has emerged as a potential player in OC prognosis, with studies indicating its association with extended disease-free survival. This investigation aims to assess CT45 expression at both mRNA and protein levels in relation to recurrence and disease-free survival in OC patients undergoing treatment.

Methods

Fifty-eight confirmed ovarian cancer cases were included in this study, with tissue samples collected intraoperatively for mRNA expression analysis. mRNA expression was assessed via quantitative PCR (qPCR). Blood samples were also collected preoperatively for serum CT45 quantification using enzyme-linked immunosorbent assay (ELISA). CT45 sera was only positive for ca ovary cases. Healthy control showed no values. (p value 0.016). All patients who underwent upfront surgery followed by chemotherapy were included.

Results

Analysis revealed that OC patients significantly higher mRNA expression (<70%). Notably, 86.4% cases had higher sera CT45. High sera and FC were also associated with HGSC of OC. Whereas low sera and mRNA expression were associated with other epithelial OC. Cases with high sera CT45 and high mRNA expression demonstrated lower rates of recurrence. It was seen that at a cut off of FC<10 mRNA expression cases did not recur in more than 3 years of follow up.

Conclusions

The cases that showed High expression was associated with higher stage, aggressive variant of OC but majorly but had inability to recur. It has been previously stated by Hans et al, that CT45 is associated with aggressive variant of Hodgkins Lymphoma. As proved by Coscia et al.,more tumor cells means more platinum adducts which are identified by effector T cells and promote tumor cell killing. This can be a prognostic indicator for OC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

AIIMS, New Delhi.

Disclosure

All authors have declared no conflicts of interest.